A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Max Kates, MD
Johns Hopkins University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
95 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Vancouver Prostate Centre
Vancouver, British Columbia, Canada
- Nova Scotia Health Centre of Applied Urology Research
Halifax, Nova Scotia, Canada
- London Health Sciences Centre
London, Ontario, Canada
- University Health Network (uhn) - Princess Margaret Cancer Centre
Toronto, Ontario, Canada
- Mcgill University Health Center - Montreal General Hospital
Montreal, Quebec, Canada
- Urology Centers of Alabama Pc
Homewood, Alabama, United States
- Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
- Mayo Clinic
Scottsdale, Arizona, United States
- Arizona Institute of Urology Pllc
Tucson, Arizona, United States
- Arkansas Urology Pa
Little Rock, Arkansas, United States
- Michael G. Oefelein Md Clinical Trials
Bakersfield, California, United States
- Tower Urology
Los Angeles, California, United States
- Usc/keck Department of Urology
Los Angeles, California, United States
- Sun Kim Urology
Orange, California, United States
- University of California Irvine Medical Center (ucimc)
Orange, California, United States
- University of California Davis Cancer Center
Sacramento, California, United States
- Stanford University School of Medicine
Stanford, California, United States
- Colorado Clinical Research
Aurora, Colorado, United States
- Urology Associates, Pc
Lone Tree, Colorado, United States
- Hartford Healthcare Medical Group
Hartford, Connecticut, United States
- Medstar Washington Hospital Center
Washington D.C., District of Columbia, United States
- Advanced Urology Institute
Daytona Beach, Florida, United States
- Mayo Clinic Cancer Center
Jacksonville, Florida, United States
- Lakeland Regional Health
Lakeland, Florida, United States
- Advanced Urology Institute, Llc
Largo, Florida, United States
- University of Miami
Miami, Florida, United States
- Emory Winship Cancer Center
Atlanta, Georgia, United States
- Velocity Clinical Research- Savanah Urological Associates
Savannah, Georgia, United States
- Rush University Medical Center
Chicago, Illinois, United States
- University of Chicago
Chicago, Illinois, United States
- Uropartners Llc
Glenview, Illinois, United States
- Duly Health and Care
Lisle, Illinois, United States
- Urology of Indiana, Llc
Carmel, Indiana, United States
- Urology of Indiana
Greenwood, Indiana, United States
- Urology Center of Iowa Research
West Des Moines, Iowa, United States
- the University of Kansas Cancer Center
Westwood, Kansas, United States
- Wichita Urology Group
Wichita, Kansas, United States
- First Urology, Psc
Louisville, Kentucky, United States
- Southern Urology
Lafayette, Louisiana, United States
- Regional Urology, Llc
Shreveport, Louisiana, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Dec 2023
- Primary completion
- 30 Nov 2026
- Completion
- 28 Feb 2029
- Last update posted
- 1 Jul 2026
- Registered enrollment
- 367
- Registry id
- NCT06111235
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.